Review ArticleThe Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Keywords
Cited by (0)
Disclosure: Dr. Beasley reports receiving other assistance from Loxo Oncology outside of the submitted work. Dr. Botling reports receiving grants and personal fees from AstraZeneca, Merck Sharp & Dohme, Roche Holdings AG, Pfizer, Boehringer Ingelheim, Novartis, Illumina, and Bristol Myers Squibb outside of the submitted work. Dr. Bubendorf reports receiving personal fees from Bristol Myers Squibb; and grants and personal fees from Merck Sharp & Dohme and Roche Holdings AG during the conduct of the study. Dr. Hwang reports receiving grants from AstraZeneca; grants and personal fees from Merck, Novartis, and Takeda; and personal fees from Roche, Bayer, and Pfizer outside of the submitted work. Dr. Longshore reports receiving grants from Agilent Technologies; grants and personal fees from Roche Diagnostics, AstraZeneca, and Biodesix; and personal fees from Bristol Myers Squibb, Genentech, Merck, Pfizer, AbbVie, Bayer, Loxo Oncology, and Spectrum pharmaceuticals outside of the submitted work. Dr. Lopez-Rios reports receiving grants and personal fees from Thermo Fisher and Bristol Myers Squibb during the conduct of the study; and personal fees from Thermo Fisher, Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, Roche Holdings AG, Eli Lilly, AstraZeneca, and Bayer outside of the submitted work. Dr. Mino-Kenudson reports receiving grants from Novartis; and personal fees from H3 Biomedicine, and AstraZeneca outside of the submitted work. Dr. Nicholson reports receiving grants and personal fees from Pfizer and personal fees from Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol Myers Squibb, Roche Holdings AG, AbbVie, and Oncologica outside of the submitted work. Dr. Peters reports receiving personal fees from AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Bistrol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar S.A., Pfizer, Regeneron, Sanofi, Seattle Genetics, and Takeda; nonfinancial support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Clovis, F. Hoffmann La Roche, Illumina, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, and Sanofi; and personal fees from Bioinvent outside of the submitted work. Dr. Wistuba reports receiving grants and personal fees from Genentech/Roche, Bayer, Bristol Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck, and Guardant Health; and personal fees from GlaxoSmithKline and Merck Sharp & Dohme; grants from Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Johnson & Johnson, Karus, Iovance, 4D, Oncocyte, Novartis, and Akoya outside of the submitted work; Dr. Tsao reports receiving grants and personal fees from Merck, Bayer, and AstraZeneca; and personal fees from Bristol-Meyers Squibb, Hoffmann La Roche, Takeda, and Amgen outside of the submitted work. The remaining authors declare no conflict of interest.